FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2996985711> ?p ?o ?g. }

• W2996985711 endingPage "536" @default.
• W2996985711 startingPage "536" @default.
• W2996985711 abstract "Background: Acute myeloid leukemia (AML) is a malignant clonal disease of hematopoietic stem cells. The long term survival of AML is not satisfactory, so new treatment should be explored. Here, we show that chidamide(CH), a histone deacetylase inhibitor, combined with decitabine(DE) induces apoptosis of AML cell lines and primary refractory/relapsed AML cells by up-regulating PERP. This may provide a new option for AML treatment. Methods and results: We first examined the half-inhibitory concentrations (IC50) of chidamide and decitabine against THP-1, MV4-11, HL60 and Kasumi-1 cell lines using MTT (Fig1 A-D). And the drug combination is performed according to the IC50. In the double-drug combination experiment, we used MTT to detect the effect of drugs on the proliferation of the four cell lines (Fig1 E-H), used calcusyn 2.0 software to calculate the synergistic effect (Fig2), flow cytometry to detect apoptosis (Fig3 A-D), and western blot to detect the pro-apoptotic protein (C-CASPASE 3 and C-CASPASE 9) and anti-apoptotic proteins (CASPASE 8, BCL-2 and BCL-XL) (Fig3 E-H). We found that chidamide combined with decitabine synergistically inhibited proliferation of AML cell lines, induced apoptosis, up-regulated pro-apoptotic protein levels and down-regulated anti-apoptotic protein levels. To investigate this combination therapeutic effect in vivo, we selected 5 refractory/relapsed AML patients, extracted primary AML cells, and used ATP chemiluminescence kit for drug sensitivity test. The results confirmed that four of the five patients with AML showed sensitivity to combinations (Fig4). To further explore the mechanism of action of CH combination with DE, we performed transcriptome sequencing (Fig5). Analysis of the sequencing results, the gene PERP, which shows the significant difference in the apoptotic pathway, was further examined. The PERP is a new member of the PMP-22/GAS3 family as an apoptosis-associated target of TP53. RT-QPCR and WB verified the role of PERP in apoptosis in DE and CH combination (Fig6). The results showed that the combination could up-regulate the PERP gene than the single drug. When we explored the role of the PERP gene in AML cell lines, we knocked down the PERP gene by lentivirus and detected cell proliferation after infection. Pretreated AML cell lines by lentivirus-infection (Fig7A-F), then we tested for proliferation (Fig7G-I) (Fig8A-C), apoptosis (Fig8D-E), and pro-apoptotic protein expression (Fig8G-I). The results showed that knocking down the PERP gene promoted the proliferation of AML cell lines and attenuated the sensitivity of AML cell lines to chemotherapeutic drugs. We also compare the mRNA level of PERP between 35 AML patients and 20 normal and found that the PERP mRNA of AML patients was significantly lower than the normal (Fig9). MV4-11 cells were exposed to CH and DE alone or in combination, and proteomic sequencing was performed to examine the effect of the drug on cellular protein. The result indicates to some extent that CH contributes more to the combined effect. And the drug causes changes in multiple pathways in the cell (Fig10). Conclusion: Our experiments revealed that CH combined with DE may have therapeutic effects on AML and, to some extent, reveal the mechanism of dual drug combination. Legends to figures Fig1. 50% inhibitory concentration (IC50) values of chidamide and decitabine alone treated AML cell lines. Fig2. Chidamide acts synergistically in AML with DE. Fig3. Chidamide in combination with decitabine significantly induced apoptosis in AML cell lines. Fig4. The sensitivity of relapsed or refractory AML primary cells to chidamide and decitabine alone or in combination. Fig5. Gene expression analysis showed an obvious difference based on treatment. Fig6. Verify transcriptome sequencing results by real-time QPCR and by western blotting with or without drug treatment. Fig7. The effect of down-regulation of PERP by Lentivirus-mediated RNAi on AML cells proliferation. Fig8. PERP knockdown causes AML cells to develop resistance to combination drugs. Fig9.The level of PERP mRNA in peripheral blood mononuclear cells of AML and normal humans. Fig10. Proteomics sequencing results show the differentially expressed protein and a cluster analysis of the functions or pathways enriched by differentially expressed proteins in GO and KEGG pathways compared to single agents. Disclosures No relevant conflicts of interest to declare." @default.
• W2996985711 created "2020-01-10" @default.
• W2996985711 creator A5030343111 @default.
• W2996985711 creator A5053780153 @default.
• W2996985711 creator A5067915781 @default.
• W2996985711 date "2019-11-13" @default.
• W2996985711 modified "2023-10-16" @default.
• W2996985711 title "Chidamide Combined with Decitabine Synergistically Induce Apoptosis of Acute Myeloid Leukemia By up-Regulating Perp gene In Vivo and in Vitro" @default.
• W2996985711 doi "https://doi.org/10.1182/blood-2019-123876" @default.
• W2996985711 hasPublicationYear "2019" @default.
• W2996985711 type Work @default.
• W2996985711 sameAs 2996985711 @default.
• W2996985711 citedByCount "0" @default.
• W2996985711 crossrefType "journal-article" @default.
• W2996985711 hasAuthorship W2996985711A5030343111 @default.
• W2996985711 hasAuthorship W2996985711A5053780153 @default.
• W2996985711 hasAuthorship W2996985711A5067915781 @default.
• W2996985711 hasConcept C104317684 @default.
• W2996985711 hasConcept C150194340 @default.
• W2996985711 hasConcept C150903083 @default.
• W2996985711 hasConcept C185592680 @default.
• W2996985711 hasConcept C190283241 @default.
• W2996985711 hasConcept C190727270 @default.
• W2996985711 hasConcept C203014093 @default.
• W2996985711 hasConcept C207001950 @default.
• W2996985711 hasConcept C2778461978 @default.
• W2996985711 hasConcept C2778729363 @default.
• W2996985711 hasConcept C2778903051 @default.
• W2996985711 hasConcept C2780235182 @default.
• W2996985711 hasConcept C2780783641 @default.
• W2996985711 hasConcept C502942594 @default.
• W2996985711 hasConcept C54355233 @default.
• W2996985711 hasConcept C55493867 @default.
• W2996985711 hasConcept C81885089 @default.
• W2996985711 hasConcept C86803240 @default.
• W2996985711 hasConcept C98274493 @default.
• W2996985711 hasConceptScore W2996985711C104317684 @default.
• W2996985711 hasConceptScore W2996985711C150194340 @default.
• W2996985711 hasConceptScore W2996985711C150903083 @default.
• W2996985711 hasConceptScore W2996985711C185592680 @default.
• W2996985711 hasConceptScore W2996985711C190283241 @default.
• W2996985711 hasConceptScore W2996985711C190727270 @default.
• W2996985711 hasConceptScore W2996985711C203014093 @default.
• W2996985711 hasConceptScore W2996985711C207001950 @default.
• W2996985711 hasConceptScore W2996985711C2778461978 @default.
• W2996985711 hasConceptScore W2996985711C2778729363 @default.
• W2996985711 hasConceptScore W2996985711C2778903051 @default.
• W2996985711 hasConceptScore W2996985711C2780235182 @default.
• W2996985711 hasConceptScore W2996985711C2780783641 @default.
• W2996985711 hasConceptScore W2996985711C502942594 @default.
• W2996985711 hasConceptScore W2996985711C54355233 @default.
• W2996985711 hasConceptScore W2996985711C55493867 @default.
• W2996985711 hasConceptScore W2996985711C81885089 @default.
• W2996985711 hasConceptScore W2996985711C86803240 @default.
• W2996985711 hasConceptScore W2996985711C98274493 @default.
• W2996985711 hasIssue "Supplement_1" @default.
• W2996985711 hasLocation W29969857111 @default.
• W2996985711 hasOpenAccess W2996985711 @default.
• W2996985711 hasPrimaryLocation W29969857111 @default.
• W2996985711 hasRelatedWork W1997436698 @default.
• W2996985711 hasRelatedWork W2142279727 @default.
• W2996985711 hasRelatedWork W2348512307 @default.
• W2996985711 hasRelatedWork W2373572728 @default.
• W2996985711 hasRelatedWork W2523150743 @default.
• W2996985711 hasRelatedWork W2623745898 @default.
• W2996985711 hasRelatedWork W2758043227 @default.
• W2996985711 hasRelatedWork W2900063795 @default.
• W2996985711 hasRelatedWork W2982691941 @default.
• W2996985711 hasRelatedWork W4283690075 @default.
• W2996985711 hasVolume "134" @default.
• W2996985711 isParatext "false" @default.
• W2996985711 isRetracted "false" @default.
• W2996985711 magId "2996985711" @default.
• W2996985711 workType "article" @default.